Description
Description
The trade name of Shingles Vaccine is SHINGRIX, which was developed by GlaxoSmithKline. Its product was firstly approved in China in 2020. Recombinant zoster vaccine is suitable for adults aged 50 years and over to protect against shingles (herpes zoster). The recombinant zoster vaccine has been listed in the Chinese market. By 2020, Glaxo SmithKline Biologicals is the only manufacturer in the Chinese Shingles Vaccine market.
According to CRI’s market research, since Shingles Vaccine entered the Chinese market in 2020, its annual sales value reached CNY2 million, and its annual sales volume reached 1,745 doses. Therefore, the development prospects are quite good.
According to CRI analysis, from 2021 to 2025, as Shingles Vaccine market expands, its sales will continue to grow. Compared with Merck’s Zostavax, SHINGRIX has better preventive effects and faster replacement velocity. Therefore, as the market share of Shingles Vaccine will gradually increase, and sales and sales volume will also increase.
Topics Covered:
-The impact of COVID-19 on China’s Shingles Vaccine market
– Sales value of China’s Shingles Vaccine 2016-2020
– Competitive landscape of China’s Shingles Vaccine market
– Prices of Shingles Vaccine in China
– Prices of Shingles Vaccine in China by regions and manufacturers
– Analysis on factors affecting the development of China’s Shingles Vaccine market
– Prospect of China’s Shingles Vaccine market from 2021 to 2025